Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. [electronic resource]
Producer: 20150112Description: 2015-20 p. digitalISSN:- 1791-2431
- Animals
- B-Lymphocytes -- immunology
- Benzamides -- therapeutic use
- DNA-Binding Proteins -- genetics
- Drug Therapy, Combination
- Female
- Imatinib Mesylate
- Interferon-gamma -- biosynthesis
- Interleukin-2 -- therapeutic use
- Killer Cells, Natural -- immunology
- Lung Neoplasms -- drug therapy
- Melanoma, Experimental -- drug therapy
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Piperazines -- therapeutic use
- Pyrimidines -- therapeutic use
- Skin Neoplasms -- drug therapy
- T-Lymphocytes -- immunology
- Tumor Necrosis Factor Receptor Superfamily, Member 7 -- biosynthesis
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.